ReviewPublished 9 October 2026Progress on therapeutic mRNA vaccines for cancerSiyu Wu · Huarong Liao · Wei ZhangFrontiers in Oncologydoi 10.3389/fonc.2026.1980190
ReviewPublished 8 October 2026Leishmaniasis and vaccine development: current progress, challenges, and future perspectivesSomaditya Dey · Anushka Ghosh · Debarati MukherjeeFrontiers in Cellular and Infection Microbiologydoi 10.3389/fcimb.2026.1929424
PerspectivePublished 17 September 2026From outbreak response to regional readiness: reimagining mRNA vaccine platforms for Ebola preparedness in East AfricaUgwu Okechukwu Paul-Chima · Martin NduwimanaFrontiers in Tropical Diseasesdoi 10.3389/fitd.2026.1887687
Hypothesis and TheoryPublished 24 July 2026The biological memory buffer hypothesis: can programmable nanocarriers shape cellular memory to improve the durability of mRNA vaccines and gene therapies?Okechukwu Paul-Chima Ugwu · Chinyere Nneoma Ugwu · Godson Emeka Anyanwu · Mariam Basajja · Maryann Chiamaka EbuohFrontiers in Drug Deliverydoi 10.3389/fddev.2026.1902184
ReviewPublished 4 June 2026Porcine rotavirus type A VP8 protein: an antigen with dual functions as a subunit vaccine and serological diagnostic agent, from receptor binding to mucosal and systemic immunityZhang Zhen · Liu Shuhua · Ma Baihe · Chen Xin · Guo Meiliang · Liang Fanxin · Li LianruiFrontiers in Virologydoi 10.3389/fviro.2026.1859126
Mini ReviewPublished 20 March 2026Beyond mutations: personalising oncology via RNA-editingIvo Fierro-MontiFrontiers in RNA Researchdoi 10.3389/frnar.2026.1779364
RNA ResearchPublished 1 October 2024The expanding role of cap-adjacent modifications in animalsEleanor Bellows · Rupert G. Fray · Helen M. Knight · Nathan ArcherFrontiers in RNA Researchdoi 10.3389/frnar.2024.1485307
